Pharma Major Lupin (Lupin) today announced that it has entered into a strategic asset purchase agreement with German-based Temmler pharma, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.

Temmler has a fast growing specialty portfolio of 13 products including key Central Nervous System (CNS) products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease, as well as fast-growing dermatology products for anti-wart treatment.

Since Huntington disease has many symptoms ranging from motoric symptoms to personality changes, both Temmler and Hormosan products can be used to treat the disease.

Commenting on the acquisition, Ms Vinita Gupta, CEO of Lupin said, "...Temmler's business has a strong strategic fit with Lupin's Hormosan business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to the German market."

Dr Maurice Chagnaud, president - Europe and head of inhalation strategy, commented, "....Temmler operates in niche segments and its specialty product portfolio has strong synergies with Hormosan's existing CNS portfolio. The acquisition not only complements but would also enhance Hormosan's specialty portfolio and enables it to grow into niche therapy areas.